EU regulator backs Gilead's twice-yearly injection for HIV prevention

EU regulator backs Gilead's twice-yearly injection for HIV prevention

GILD
Neutral
Market
EU regulator backs Gilead's twice-yearly injection for HIV prevention

Summary

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection,...

The European Union's drugs regulator has recommended approval of Gilead Sciences' lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents, the drugmaker said on Friday.

Tags

GILD
Related Articles
Gilead (GILD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
GILD
Positive
Gilead Receives Positive CHMP Opinions Under Accelerated Review From European Medicines Agency for Twice-Yearly Lenacapavir for HIV Prevention
GILD
Neutral
GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm
GILD
Negative